BG108155A - Device for selective suppression of pathologic dna-specific b cells - Google Patents

Device for selective suppression of pathologic dna-specific b cells

Info

Publication number
BG108155A
BG108155A BG108155A BG10815503A BG108155A BG 108155 A BG108155 A BG 108155A BG 108155 A BG108155 A BG 108155A BG 10815503 A BG10815503 A BG 10815503A BG 108155 A BG108155 A BG 108155A
Authority
BG
Bulgaria
Prior art keywords
specific
pathologic
dna
cells
selective suppression
Prior art date
Application number
BG108155A
Other languages
Bulgarian (bg)
Other versions
BG65715B1 (en
Inventor
Чавдар ВАСИЛЕВ
Андрей ЧОРБАНОВ
Вихра ЙОМТОВА
Original Assignee
Чавдар ВАСИЛЕВ
Андрей ЧОРБАНОВ
Вихра ЙОМТОВА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чавдар ВАСИЛЕВ, Андрей ЧОРБАНОВ, Вихра ЙОМТОВА filed Critical Чавдар ВАСИЛЕВ
Priority to BG108155A priority Critical patent/BG65715B1/en
Priority to PCT/BG2004/000010 priority patent/WO2005023871A1/en
Publication of BG108155A publication Critical patent/BG108155A/en
Publication of BG65715B1 publication Critical patent/BG65715B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a device for selective suppression of pathologic DNA-specific B cells, in particular in the system lupus erythematosus, which is a bi-specific chimerical monoclonal antibody. The invention also relates to a method for the preparation of the chimerical monoclonal antibody and to its administration for selective suppression of pathologic DNA-specific B cells.
BG108155A 2003-09-04 2003-09-04 Device for selective suppression of pathologic dna-specific b cells BG65715B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BG108155A BG65715B1 (en) 2003-09-04 2003-09-04 Device for selective suppression of pathologic dna-specific b cells
PCT/BG2004/000010 WO2005023871A1 (en) 2003-09-04 2004-06-08 An agent for selective suppression disease-associated auto-reactive b-cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG108155A BG65715B1 (en) 2003-09-04 2003-09-04 Device for selective suppression of pathologic dna-specific b cells

Publications (2)

Publication Number Publication Date
BG108155A true BG108155A (en) 2005-06-30
BG65715B1 BG65715B1 (en) 2009-08-31

Family

ID=34230300

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108155A BG65715B1 (en) 2003-09-04 2003-09-04 Device for selective suppression of pathologic dna-specific b cells

Country Status (2)

Country Link
BG (1) BG65715B1 (en)
WO (1) WO2005023871A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG65954B1 (en) * 2005-01-05 2010-07-30 Чавдар ВАСИЛЕВ Means for selective suppression of the activity of pathologic autoreactive b-cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232522B1 (en) * 1990-01-31 2001-05-15 Oklahoma Medical Research Foundation Non-human animal model for systemic lupus erythematosis
GB9516760D0 (en) * 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
US6001964A (en) * 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
CN1307590A (en) * 1998-02-17 2001-08-08 米德列斯公司 Treating and diagnosing macrophage-mediated diseases using FC receptor ligands
US6265101B1 (en) * 1998-08-21 2001-07-24 Eveready Battery Company, Inc. Battery constructions having increased internal volume for active components
FR2796953B1 (en) * 1999-07-29 2003-10-10 Centre Nat Rech Scient RECOMBINANT PROTEINS, AND MOLECULAR COMPLEXES DERIVED FROM SUCH PROTEINS, ANALOGS TO MOLECULES INVOLVED IN IMMUNE RESPONSES
JP2001061471A (en) * 1999-07-29 2001-03-13 Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh Cell line derived from cell line 2.4G2 and not preferably producing mouse kappa chain
EP1212366B1 (en) * 1999-07-30 2007-09-12 Medarex, Inc. Therapeutic compounds comprised of anti-fc receptor binding agents
DE60123238T2 (en) * 2000-06-05 2007-05-03 University of Tennessee Corp., Knoxville COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ATE423571T1 (en) * 2001-10-12 2009-03-15 Schering Corp USE OF BISPECIFIC ANTIBODIES AGAINST AN ACTIVATIVE RECEPTOR FCEPSILONRI AND AGAINST AN INHIBITING RECEPTOR OX2RA (CD200RA) TO REGULATE IMMUNE RESPONSES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG65954B1 (en) * 2005-01-05 2010-07-30 Чавдар ВАСИЛЕВ Means for selective suppression of the activity of pathologic autoreactive b-cells

Also Published As

Publication number Publication date
BG65715B1 (en) 2009-08-31
WO2005023871A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
UA92505C2 (en) Anti-cd3 antibody formulations
WO2004099249A3 (en) Optimized fc variants and methods for their generation
IL195338A0 (en) Optimized fc variants and methods for their generation
MXPA04003291A (en) Use of bispecific antibodies to regulate immune responses.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2006121422A8 (en) Antibodies against clostridium difficile toxins and uses thereof
MX2007002675A (en) Humanized anti-beta7 antagonists and uses therefor.
WO2005047512A3 (en) Plasmid system for multigene expression
TW200510459A (en) RG1 antibodies and uses thereof
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
EP1519747A4 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
YU28503A (en) Humanized anti-lt-betha-r antibodies
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
NZ588674A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP1135415A4 (en) Humanized antibodies to gamma-interferon
ZA200701656B (en) Humanized anti-cment antagonists
WO2007041171A3 (en) Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
TW200607815A (en) Anti-CD148 antibodies and binding epitopes therefor
WO2007114861A3 (en) Il-21 receptor antagonists
PL1711531T3 (en) Neutralizing anti tlr4/md-2 antibodies and methods of use thereof
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies